Elucidating the molecular basis of MSH2‐deficient tumors by combined germline and somatic analysis
Sign Up to like & getrecommendations! Published in 2017 at "International Journal of Cancer"
DOI: 10.1002/ijc.30820
Abstract: In a proportion of patients presenting mismatch repair (MMR)‐deficient tumors, no germline MMR mutations are identified, the so‐called Lynch‐like syndrome (LLS). Recently, MMR‐deficient tumors have been associated with germline mutations in POLE and MUTYH or… read more here.
Keywords: deficient; msh2; deficient tumors; analysis ... See more keywords
A comprehensive analysis of BRCA2 gene: focus on mechanistic aspects of its functions, spectrum of deleterious mutations, and therapeutic strategies targeting BRCA2-deficient tumors
Sign Up to like & getrecommendations! Published in 2018 at "Medical Oncology"
DOI: 10.1007/s12032-018-1085-8
Abstract: BRCA2is the main susceptibility gene known to be involved in the pathogenesis of breast cancer. It plays an important role in maintaining the genome stability by homologous recombination through DNA double-strand breaks repairing, by interacting… read more here.
Keywords: deficient tumors; brca2; brca2 deficient; brca2 gene ... See more keywords
SWI / SNF Nucleosome Complex-Deficient Colorectal Carcinomas Have Distinct Clinicopathologic Features.
Sign Up to like & getrecommendations! Published in 2020 at "Human pathology"
DOI: 10.1016/j.humpath.2020.03.009
Abstract: The switch/sucrose-nonfermenting (SWI/SNF) nucleosome complex consists of several proteins that are involved in cellular proliferation and tumor suppression. The aim of this study was to correlate immunohistochemical expression of four SWI/SNF complex subunits, SMARCA2, SMARCB1,… read more here.
Keywords: deficient; deficient tumors; complex deficient; swi snf ... See more keywords
PLX038: a long-acting topoisomerase I inhibitor with robust anti-tumor activity in ATM deficient tumors and potent synergy with PARP inhibitors.
Sign Up to like & getrecommendations! Published in 2022 at "Molecular cancer therapeutics"
DOI: 10.1158/1535-7163.mct-22-0217
Abstract: Alterations in the ATM gene are among the most common somatic and hereditary cancer mutations, and ATM-deficient tumors are hypersensitive to DNA damaging agents. A synthetic lethal combination of DNA damaging agents and DNA repair… read more here.
Keywords: atm deficient; deficient; deficient tumors; topoisomerase inhibitor ... See more keywords
Abstract 333: USP1 is required for replication fork stability in BRCA1-deficient tumors
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-333
Abstract: Homologous-recombination (HR) deficient tumors with BRCA1 and BRCA2 mutations exhibit replication fork stability defects. To date, PARP inhibitors are the only targeted therapy available in the clinic against HR deficient tumors, and alternative therapies are… read more here.
Keywords: replication fork; deficient tumors; brca1 deficient; fork ... See more keywords
Ewing Sarcomas Phenocopy BRCA1-Deficient Tumors.
Sign Up to like & getrecommendations! Published in 2018 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-rw2018-045
Abstract: Transcriptional dysregulation promotes R-loops and impairs homologous recombination in Ewing sarcoma. read more here.
Keywords: ewing sarcomas; deficient tumors; phenocopy brca1; brca1 deficient ... See more keywords
Immune desert in MMR-deficient tumors predicts poor responsiveness of immune checkpoint inhibition
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2023.1142862
Abstract: Background Although many efforts have been devoted to identify biomarkers to predict the responsiveness of immune checkpoint inhibitors, including expression of programmed death-ligand 1 (PD-L1) and major histocompatibility complex (MHC) I, microsatellite instability (MSI), mismatch… read more here.
Keywords: immune checkpoint; mmr deficient; deficient tumors; immune ... See more keywords